Laboratory of Nanomedicine and Molecular Imaging was established in 2012, focusing on the exploration of cancer-targeted multifunctional nanoparticles with clinical potential for achieving multimodal cancer imaging with ultra-sensitivity and enhanced spatial resolution, as well as effective cancer therapy. Currently, our primary research interest is to design and develop novel nanomaterials such as ultrasmall theranostic protein nanoparticles, stimuli-responsive polymeric nanoparticles with synergistic effect, self-assembled fluorophore nanostructure, as well as novel dosage forms for precise cancer imaging, and targeted/personalized cancer therapy.

Currently, our Laboratory consists of 4 full professors, 3 associate professors, 1 assistant professor, as well as more than 30 graduates and postdocs. The lab members have diverse backgrounds in organic chemistry, polymeric synthesis, pharmaceutics, and cancer biology. The laboratory has strong research facilities for organic synthesis, construction of inorganic nanomaterials, structure and physicochemical characterization, in vitro cell studies, in vivo cancer imaging (e.g. MRI, CT, SPECT/CT, photoacoustics, and fluorescence), and in vivo therapeutic efficacy. Our research has also been supported by several national funding agencies. To date, the laboratory has published over 30 papers in peer-reviewed journals with impact factors of more than 10.0 since 2013, including Adv Mater, J Am Chem Soc, ACS Nano, Adv Funct Mater, Biomaterials, Theranostics, and Small.